Ferlay J SI, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. et al. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. GLOBOCAN 2012 v1.0 2013 [cited 2014 november]; Available from: http://globocan.iarc.fr
Ploeg M et al. The present and future burden of urinary bladder cancer in the world. World journal of urology 2009; 27(3): 289-93.
van Tilborg AA et al. Selection of microsatellite markers for bladder cancer diagnosis without the need for corresponding blood. PloS one 2012; 7(8): e43345.
di Martino E et al. An integrated genomic, transcriptional and protein investigation of FGFRL1 as a putative 4p16.3 deletion target in bladder cancer. Genes, chromosomes & cancer 2013; 52(9): 860-71.
Lopez-Beltran A et al. Loss of heterozygosity at 9q32-33 (DBC1 locus) in primary non-invasive papillary urothelial neoplasm of low malignant potential and low-grade urothelial carcinoma of the bladder and their associated normal urothelium. The Journal of pathology 2008; 215(3): 263-72.
Ploussard G et al. Prognostic value of loss of heterozygosity at chromosome 9p in non-muscle-invasive bladder cancer. Urology 2010; 76(2): 513 e13-8.
Lopez-Beltran A et al. Urothelial carcinoma of the bladder, lipid cell variant: clinicopathologic findings and LOH analysis. The American journal of surgical pathology 2010; 34(3): 371-6.
Szarvas T. [The diagnostic value of microsatellite LOH analysis and the prognostic relevance of angiogenic gene expression in urinary bladder cancer]. Magyar onkologia 2009; 53(4): 385-9.
Zieger K et al. Consistent genomic alterations in carcinoma in situ of the urinary bladder confirm the presence of two major pathways in bladder cancer development. International journal of cancer. Journal international du cancer 2009; 125(9): 2095-103.
Grigorov E et al. Applied pharmacoeconomics - methodology, structuring and conducting of pharmacoeconomical studies. Journal of International Scientific Publications: Economy & Business 2013; 7(1): 540-551.
Bouffioux C et al. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group. The Journal of urology 1995; 153(3 Pt 2): 934-41.
Kaasinen E et al. Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma. European urology 2002; 42(2): 167-74.
Tolley DA et al. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. The Journal of urology 1996; 155(4): 1233-8.
Brocks CP et al. Inhibition of tumor implantation by intravesical gemcitabine in a murine model of superficial bladder cancer. The Journal of urology 2005; 174(3): 1115-8.
Pan JS et al. Inhibition of implantation of murine bladder tumor by thiotepa in cauterized bladder. The Journal of urology 1989; 142(6): 1589-93.
Pode D et al. The mechanism of human bladder tumor implantation in an in vitro model. The Journal of urology 1986; 136(2): 482-6.
Gunther JH et al. Optimizing syngeneic orthotopic murine bladder cancer (MB49). Cancer research 1999; 59(12): 2834-7.
Bohle A et al. Inhibition of bladder carcinoma cell adhesion by oligopeptide combinations in vitro and in vivo. The Journal of urology 2002; 167(1): 357-63.
Oddens JR et al. One immediate postoperative instillation of chemotherapy in low risk Ta, T1 bladder cancer patients. Is it always safe? European urology 2004; 46(3): 336-8.
Чакъров С. Рак на пикочния мехур. Health.bg – нефрология, урология, андрология 2013; 6: 34-37.
Shelley MD et al. Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses. Cancer treatment reviews 2010; 36(3): 195-205.
Sylvester RJ et al. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. The Journal of urology 2004; 171(6 Pt 1): 2186-90, quiz 2435.
Volpe A et al. Mitomycin C for the treatment of bladder cancer. Minerva urologica e nefrologica = The Italian journal of urology and nephrology 2010; 62(2): 133-44.
Grossman HB et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. The New England journal of medicine 2003; 349(9): 859-66.
Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. Lancet 1999; 354(9178): 533-40.
Kachnic LA et al. Bladder preservation by combined modality therapy for invasive bladder cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997; 15(3): 1022-9.
Bajorin DF et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999; 17(10): 3173-81.
Sternberg CN et al. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. The Journal of urology 1988; 139(3): 461-9.
Logothetis CJ et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990; 8(6): 1050-5.
Loehrer PJ, Sr. et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992; 10(7): 1066-73.
Kaufman D et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000; 18(9): 1921-7.
Moore MJ et al. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999; 17(9): 2876-81.
von der Maase H et al. Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999; 10(12): 1461-5.
Weight CJ et al. Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial car
cinoma of the bladder: a contemporary series. Cancer 2009; 115(4): 792-9.
Sternberg CN et al. Can patient selection for bladder preservation be based on response to chemotherapy? Cancer 2003; 97(7): 1644-52.
Caffo O et al. Gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer: Long-term cumulative results of 2 prospective single-institution studies. Cancer 2011; 117(6): 1190-6.
Skinner DG et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. The Journal of urology 1991; 145(3): 459-64; discussion 464-7.
von der Maase H et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005; 23(21): 4602-8.
Sternberg CN. Perioperative chemotherapy in muscle-invasive bladder cancer to enhance survival and/or as a strategy for bladder preservation. Seminars in oncology 2007; 34(2): 122-8.
Stadler WM et al. Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer. Urologic oncology 2002; 7(4): 153-7.
Lehmann J et al. Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005; 23(22): 4963-74.
NCCN. Clinical Practice Guidelines in Oncology:Bladder Cancer. v.1.2013. 2013 [cited 2015 08.02.2015]; Available from: http://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf.
Waxman J et al. New combination chemotherapy programme for bladder cancer. British journal of urology 1989; 63(1): 68-71.
Bellmunt J et al. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer 1997; 80(10): 1966-72.
Morales A et al. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. The Journal of urology 1976; 116(2): 180-3.
Kavoussi LR et al. Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response. The Journal of clinical investigation 1990; 85(1): 62-7.
Ratliff TL et al. Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. The Journal of urology 1987; 137(1): 155-8.
Ratliff TL et al. Role of fibronectin in intravesical BCG therapy for superficial bladder cancer. The Journal of urology 1988; 139(2): 410-4.
Mungan NA et al. Bacille Calmette-Guerin in superficial transitional cell carcinoma. British journal of urology 1998; 82(2): 213-23.
O`Donnell MA et al. Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed. The Journal of urology 2001; 166(4): 1300-4, discussion 1304-5.
Knight-Shapiro C et al. The relationship between delayed type hypersensitivity and acquired cellular resistance in experimental airborne tuberculosis. Journal of hygiene, epidemiology, microbiology, and immunology 1975; 19(4): 421-4.
Bohle A et al. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. The Journal of urology 2003; 169(1): 90-5.
Smith JA, Jr. et al. Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association. The Journal of urology 1999; 162(5): 1697-701.
Lamm DL. BCG immunotherapy for transitional-cell carcinoma in situ of the bladder. Oncology (Williston Park) 1995; 9(10): 947-52, 955, discussion 955-65.
Sylvester RJ et al. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. The Journal of urology 2002; 168(5): 1964-70.
Lamm DL et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. The Journal of urology 2000; 163(4): 1124-9.
Oosterlinck W et al. [EAU Recommendations 2001. `Guidelines on bladder cancer`]. Progres en urologie : journal de l`Association francaise d`urologie et de la Societe francaise d`urologie 2002; 12(5): 1161-3.
Glashan RW. A randomized controlled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder. The Journal of urology 1990; 144(3): 658-61.
Boccardo F et al. Prophylaxis of superficial bladder cancer with mitomycin or interferon alfa-2b: results of a multicentric Italian study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 1994; 12(1): 7-13.
Belldegrun AS et al. Superficial bladder cancer: the role of interferon-alpha. The Journal of urology 1998; 159(6): 1793-801.
Ferrari P et al. Chemoimmunotherapy for prophylaxis of recurrence in superficial bladder cancer: interferon-alpha 2b versus interferon-alpha 2b with epirubicin. Anti-cancer drugs 1992; 3 Suppl 1: 25-7.
Engelmann U et al. Interferon-alpha 2b instillation prophylaxis in superficial bladder cancer--a prospective, controlled three-armed trial. Project Group Bochum--Interferon and Superficial Bladder Cancer. Anti-cancer drugs 1992; 3 Suppl 1: 33-7.
Stricker P et al. Bacillus Calmette-Guerin plus intravesical interferon alpha-2b in patients with superficial bladder cancer. Urology 1996; 48(6): 957-61; discussion 961-2.
Linn JF et al. Keyhole limpet haemocyanin in experimental bladder cancer: literature review and own results. European urology 2000; 37 Suppl 3: 34-40.
Jurincic CD et al. Immunotherapy ins bladder cancer with keyhole-limpet hemocyanin: a randomized study. The Journal of urology 1988; 139(4): 723-6.
Olsson CA et al. Immunologic reduction of bladder cancer recurrence rate. The Journal of urology 1974; 111(2): 173-6.
Wirguin I et al. Axonal degeneration accompanied by conduction block induced by toxin mediated immune reactivity to GM1 ganglioside in rat nerves. Journal of the neurological sciences 1995; 130(1): 17-21.
Li Y et al. The serological differentiation of acute and chronic Schistosoma japonicum infection by ELISA using keyhole limpet haemocyanin as antigen. Transactions of the Royal Society of Tropical Medicine and Hygiene 1994; 88(2): 249-51.
Moltedo B et al. Immunotherapeutic Effect of Concholepas Hemocyanin in the Murine Bladder Cancer Model: Evidence for Conserved Antitumor Properties Among Hemocyanins. THE JOURNAL OF UROLOGY® 2006; 176: 2690-2695.
Moroz LA et al. Normal human IgG with antibody activity for keyhole limpet haemocyanin. Immunology 1973; 25(3): 441-9.
Burke GP et al. Anti-keyhole limpet hemocyanin antibody in normal unsensitized individuals. The Journal of allergy and clinical immunology 1977; 59(4): 309-13.
Hortobagyi GN et al. Prognostic value of prechemotherapy skin tests in patients with metastatic breast carcinoma. Cancer 1981; 47(6): 1369-76.
Flamm J et al. Recurrent superficial transitional cell carcinoma of the bladder: adjuvant topical chemotherapy versus immunotherapy. A prospective randomized trial. The Journal of urology 1990; 144(2 Pt 1): 260-3.
Schenkman E et al. Superficial bladder cancer therapy. TheScientificWorldJournal 2004; 4 Suppl 1: 387-99.
Lammers RJ et al. Intracutaneous and intravesical immunotherapy with keyhole limpet hemocyanin compared with intravesical mitomycin in patients with non-muscle-invasive bladder cancer: results from a prospective randomized phase III trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2012; 30(18): 2273-9.
Lamm DL et al. Keyhole limpet hemocyanin immunotherapy of bladder cancer: laboratory and clinical studies. European urology 2000; 37 Suppl 3: 41-4.
Email this article (Login required) 
